Research Nester released a report titled “U.S. Non-Invasive Prenatal Testing Market: Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the U.S. non-invasive prenatal testing market in terms of market segmentation by product, by application, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The market for non-invasive prenatal testing in the United States is predicted to grow by a CAGR of 12.52% during the forecast period, i.e., 2020-2027. Further, the market is anticipated to reach USD 2,318.81 million by the end of this period. The market is segmented by product, by application and by end user. On the basis of product, the market is further segmented into Elisa kits, next generation sequencing systems and microarray analysis systems, out of which, the next generation sequencing systems segment is anticipated to hold the largest share in the market as a result of it being a new method of genome sequencing. The application segment of the market is further segmented into aneuploidy, micro-deletion, trisomy and others, out of which, the trisomy segment is estimated to grow at the highest rate over the forecast period on account of the growing use of non-invasive prenatal testing for detection of fetal trisomy. Further, based on end user, the market is segmented into hospitals, diagnostic labs, clinics and others, out of which, the hospitals segment is estimated to hold the largest share in the market as a result of growing patient population and a higher demand for improved treatments and diagnosis of chromosomal disorder in the fetal stage.

The Health Issues Caused By Chromosomal Abnormalities To Drive The Market Growth

According to the United Nations, approximately 3,000 to 5,000 children are born with Down syndrome every year. The chromosome 21 disorder has affected around 250,000 families in the United States. Chromosomal disorders, if not treated at an early stage, result in serious health disorders such as heart diseases as well as miscarriages. In order to prevent this, early diagnosis with the help of NIPT is required, which is estimated to propel the market growth. However, the strict government policies and inaccuracy of NIPT methods are predicted to restrict the market growth during the forecast period.

This report also provides the existing competitive scenario of some of the key players of the U.S. non-invasive prenatal testing market which includes company profiling of Natera Inc., F. Hoffmann La Roche Ltd., Yourgene Health plc., Illumina, Inc., Agilent Technologies, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics and Myriad Genetics. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the U.S. non-invasive prenatal testing market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.